A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The test will now be considered medically reasonable and necessary for patients over 45 with moderately elevated levels of prostate-specific antigen.
Opko logged $181.1 million in revenues from services, $26.2 million in revenue from products, and $21.5 million from licensing and intellectual property.
Get the latest news from Somos, Adaptive Biotechnologies, Thermo Fisher Scientific, and TATAA Biocenter for the week of 7/3/19.
In issuing a proposed limited local coverage determination for Opko Health's 4Kscore, Novitas changed course from a previously issued non-coverage determination.
The company reported revenues of $222.5 million, down from $254.9 million in Q1 2018, and below the consensus Wall Street estimate of $241.3 million.
While the impact on participants' bottom lines remains to be seen, some lab company leaders said they expect to see other payors explore similar plans.
A study of 10 commercial labs offering NIPT in the US found that none followed all recommendations for reporting results and informing patients and providers.